Postpartum Breast Cancer
Postpartum breast cancer (also known as pregnancy-associated breast cancer or PABC) is a form of breast cancer diagnosed during pregnancy or within five to ten years following childbirth. It is one of the most aggressive, clinically complex and scientifically understudied forms of breast cancer — disproportionately affecting young mothers at a time in their lives when the last thing they expect is a cancer diagnosis. Postpartum breast cancer is associated with a significantly poorer prognosis than breast cancers diagnosed in women who have not recently given birth — due to a combination of later diagnosis, unique and aggressive tumour biology and the profound biological changes that occur in breast tissue during and after pregnancy. Understanding the molecular mechanisms that drive postpartum breast cancer — and developing new therapeutic strategies to treat it more effectively — is one of the most important and urgent priorities in modern Cancer Biology and Medical Oncology.
Overview
Breast cancer is the most commonly diagnosed cancer in women worldwide — and while it predominantly affects older women, a significant proportion of breast cancers occur in younger women — including those who are pregnant or have recently given birth. Postpartum breast cancer accounts for approximately 30–35% of all breast cancers diagnosed in women under the age of 45 — making it far more common than many people realise.
Despite its prevalence, postpartum breast cancer has historically been significantly underresearched compared to breast cancer in older women — reflecting a broader tendency to underinvestigate cancer in younger patients. This gap in research has meant that the unique biology, risk factors and optimal treatment strategies for postpartum breast cancer are still being actively investigated by researchers around the world — including at institutions such as the University of Colorado Anschutz Medical Campus.
What Makes Postpartum Breast Cancer Different
Postpartum breast cancer is not simply breast cancer that happens to occur after childbirth — it is a biologically distinct entity with unique characteristics that distinguish it from breast cancers arising in other contexts:
The Postpartum Mammary Gland
After breastfeeding ends, the mammary gland undergoes a dramatic process of tissue remodelling called involution — in which the milk-producing cells that developed during pregnancy and lactation are eliminated and the gland returns to its pre-pregnancy state. This process involves:
- Massive cell death (apoptosis) of milk-producing cells
- Extensive remodelling of the extracellular matrix — the structural scaffolding that surrounds cells
- Recruitment of immune cells — particularly macrophages — to clear cellular debris
- Activation of tissue-remodelling enzymes
These changes create a tissue microenvironment that, in some women, promotes the survival, growth and spread of cancer cells — making the involuting mammary gland a particularly hospitable environment for tumour development and metastasis.
Aggressive Tumour Biology
Postpartum breast cancers tend to have more aggressive biological characteristics than breast cancers in non-postpartum women of similar age:
- Higher rates of lymph node involvement — Indicating earlier spread of the cancer
- Higher rates of distant metastasis — The cancer is more likely to have spread to other organs at diagnosis
- More likely to be triple-negative — Lacking oestrogen, progesterone and HER2 receptors — making them harder to treat with targeted therapies
- Higher tumour grade — Indicating more rapidly dividing and aggressive cells
- Worse prognosis — Women with postpartum breast cancer have a significantly higher risk of cancer recurrence and death than women with breast cancer not associated with pregnancy
Late Diagnosis
One of the most significant challenges in postpartum breast cancer is late diagnosis. Because young women — particularly new mothers — are not routinely screened for breast cancer, and because breast changes during and after pregnancy can mask the signs of cancer, postpartum breast cancer is frequently diagnosed at a later, more advanced stage than breast cancers in older women — significantly reducing the chances of successful treatment.
Key Molecular Mechanisms
Understanding the molecular mechanisms that drive postpartum breast cancer is a major focus of current research. Key areas of investigation include:
SEMA7A — Semaphorin 7A
One of the most exciting and promising areas of current postpartum breast cancer research is the investigation of Semaphorin 7A (SEMA7A) — a cell surface protein that plays a key role in how tumour cells adapt during postpartum involution. Research at the University of Colorado Anschutz Medical Campus — including work conducted by Dr. Nishant Kumar Rana — is investigating how SEMA7A enables cancer cells to survive the dramatic changes occurring in the postpartum breast tissue and how it promotes tumour cell adaptation, survival and metastasis during this critical period.
Understanding SEMA7A's role in postpartum breast cancer may open new therapeutic avenues — providing a molecular target for drugs that could specifically treat this aggressive and underserved form of breast cancer.
Tumour Microenvironment During Involution
The tumour microenvironment — the complex ecosystem of cells, proteins and signals surrounding a tumour — is profoundly altered during postpartum involution. Research has shown that the involuting mammary gland microenvironment is pro-tumourigenic — actively promoting the survival and spread of cancer cells through:
- Macrophage recruitment — Immune cells recruited to clear cellular debris during involution may instead promote tumour growth and spread
- Matrix metalloproteinases (MMPs) — Enzymes activated during involution to remodel the extracellular matrix may also facilitate cancer cell invasion and metastasis
- COX-2 and prostaglandin signalling — Inflammatory pathways activated during involution may promote tumour cell survival
Hypoxia and Stress Responses
Research has shown that Hypoxia — a condition of low oxygen — plays an important role in postpartum breast cancer biology — activating stress response pathways that promote cancer cell survival, angiogenesis and metastasis in the postpartum tumour microenvironment.
miRNA Regulation
MicroRNAs (miRNAs) — small non-coding RNA molecules that regulate gene expression — play important roles in postpartum breast cancer. Research is identifying specific miRNA signatures associated with postpartum breast cancer — which may serve as biomarkers for diagnosis and targets for therapy.
Risk Factors
Several factors are associated with an increased risk of postpartum breast cancer:
- Young age at first pregnancy — Women who have their first child at a younger age have a higher short-term risk of postpartum breast cancer
- Multiple pregnancies — Some studies suggest that having multiple pregnancies increases risk
- Family history — Women with a family history of breast cancer — particularly those with BRCA1 or BRCA2 mutations — have a significantly elevated risk
- Dense breast tissue — Making tumours harder to detect on mammography
- Late or no breastfeeding — Some research suggests that breastfeeding may have a protective effect against postpartum breast cancer
Diagnosis
Diagnosing postpartum breast cancer presents unique challenges:
- Breast changes during pregnancy and lactation — The normal changes in breast size, texture and density during pregnancy and breastfeeding can mask the signs of cancer
- Low clinical suspicion — Healthcare providers may not consider breast cancer in young mothers — leading to delays in diagnosis
- Imaging challenges — Dense breast tissue during and after pregnancy can reduce the sensitivity of mammography
Any persistent breast lump, thickening, skin change or other breast symptom in a pregnant or recently postpartum woman should be evaluated promptly — ideally with ultrasound and biopsy if indicated.
Treatment
The treatment of postpartum breast cancer follows general principles of breast cancer treatment — adapted to the specific context of the postpartum patient:
- Surgery — Lumpectomy or mastectomy — the primary local treatment
- Chemotherapy — Often used in postpartum breast cancer — particularly for triple-negative cancers
- Targeted Therapy — For HER2-positive cancers — using drugs such as trastuzumab
- Hormone Therapy — For hormone receptor-positive cancers — after breastfeeding has ended
- Immunotherapy — Increasingly being investigated for postpartum breast cancer — particularly triple-negative cancers
The management of postpartum breast cancer requires a multidisciplinary team — including medical oncologists, surgical oncologists, radiation oncologists, breast radiologists, pathologists and reproductive health specialists — working together to provide comprehensive, individualised care.
Research and Future Directions
Postpartum breast cancer research is a rapidly evolving field — with major research programmes at institutions including:
- University of Colorado Anschutz Medical Campus — Where researchers including Dr. Nishant Kumar Rana are investigating the role of SEMA7A and other molecular mechanisms in postpartum breast cancer biology
- University of Colorado Cancer Centre — A National Cancer Institute-designated comprehensive cancer centre with active postpartum breast cancer research programmes
- Dana-Farber Cancer Institute — A leading cancer research centre with postpartum breast cancer research programmes
- Memorial Sloan Kettering Cancer Centre — A world leader in cancer research and treatment
Key research priorities for the future include:
- Understanding the role of SEMA7A and other molecules in postpartum tumour adaptation
- Identifying biomarkers for earlier diagnosis of postpartum breast cancer
- Developing targeted therapies that specifically address the unique biology of postpartum breast cancer
- Improving screening strategies for young mothers at elevated risk
- Understanding the role of breastfeeding in modifying postpartum breast cancer risk
Postpartum Breast Cancer in India
In India, postpartum breast cancer is an important and underrecognised public health challenge. India's relatively young population and high birth rate mean that a significant proportion of breast cancers in India occur in young women — including those who have recently given birth. Improving awareness, early diagnosis and access to treatment for postpartum breast cancer in India is a critical priority — requiring investment in research, screening programmes and healthcare infrastructure.
Indian researchers — including those supported by ICMR and UGC fellowships and working at leading international institutions — are contributing to global postpartum breast cancer research — helping to build the scientific knowledge base that will ultimately improve outcomes for women with this devastating disease.